HCI-001 breast cancer PDX

Breast cancer patient-derived xenograft (PDX) model, HCI-001, one of a collection of 53 models spanning aggressive, metastatic, and treatment-resistant subtypes, that recapitulates key characteristics of original patient tumour. This model was generated from a sample of breast tumour from a Caucasian female, 40 years old with a primary diagnosis of infiltrating ductal carcinoma (IDC). The patient had no history of smoking, had no radiation therapy prior to sample collection but had undergone systemic treatment with Paclitaxel prior to collection, and had clinical metastasis to the lung.

Contributors

Inventor Institute
Alana L Welm, Yi-Chun Lin, Yoko Sakata DeRose The University of Utah Research Foundation
Cat. #: 162069
Cancer types: Breast cancer
Cancer Subtype: Infiltrating Ductal Carcinoma
Gender: Female
Cancer Stage or Grade: Stage IV, grade 3
Biopsy Site: Breast (primary)
Patient ethnicity: Caucasian
Treatment History: Pretreated: Patient had no radiation therapy prior to sample collection but had undergone systemic treatment with Paclitaxel prior to collection, and had clinical metastasis to the lung.
Primary citation: Guillen, et al. 2022. Nature Cancer. Feb; 3(2):232-250. PMID: 35221336
Product description: HCI-001 PDX: Sample from breast tumour collected from Caucasian female, with a primary diagnosis of IDC; 2007 (stage IV) and no history of smoking
Initial handling information: Implant into the cleared inguinal mammary fat pad of female Immune-compromised mice (NOD.SCID). Time to grow to 2cm: 2 months
Additional notes: Additional Information on PDX establishment: https://www.nature.com/articles/s43018-022-00337-6/figures/9
Mice Passaged: Yes
Engraftment Site: Cleared mammary fat pad
Sample Type: Tumour fragments
Host Strain: Immunocompromised mice NOD scid gamma (NSG) Jackson Laboratory 5557; NOD/scid, Jackson Laboratory 1303 or NOD rag gamma (NRG), Jackson Laboratory 7799
Histology: PAM50 subtype Basal-like
Production details: Fresh or thawed human breast tumour fragments were implanted into the cleared inguinal mammary fat pad of female Immune-compromised mice. For bone metastasis samples, bone fragments were coimplanted. For liquid specimens, pleural effusion, or ascites fluid, 1-2 milion cells were injected into cleared mammary fat pads in Matrigel. For ER+ tumours, mice were dosed with E2 beeswax pellets and given supplemental E2 via drinking water. When tumours reached 1-2 cm in diameter, tumours were aseptically collected and reimplanted into new m ice or banked. Estrogen-independent ER+ breast PDX models were generated when ER+ PDX tumours were transplated into overiectomized mice without E2 supplementation.
References:

Tufail, et al. 2024. Journal of Translational Med. Jan 3:22(1):15. PMID: 38172946

Bhattacharya, et al. 2023. Journal of Experimental & Clinical Cancer Research. Dec 16:42(1):343. PMID: 38102637

Prekovic, et al. 2023. EMBO Molecular Medicine. Dec 7:15(12):e17737. PMID: 37902007

Daneshdoust, et al. 2023. Cells. Sep 30:12(19):2338. PMID: 37830602

Wang, et al. 2023. Cell Bioscience. Dec 1:13(1):224. PMID: 38041134

Guillen, et al. 2022. Nature Cancer. Feb 3(2):232-250. PMID: 35221336

Citations And Reviews

Related Tools for PDX models

Cat. # Tool Name
152698 Anti-PALB2 [M41-P3F3] Key Info View Tool
161584 Anti-Maspin [16F7] Key Info View Tool
162071 HCI-003 breast cancer PDX Key Info View Tool
162074 HCI-006 breast cancer PDX View Tool
162080 HCI-012 breast cancer PDX Key Info View Tool

Related News

Representative example of haematoxylin and eosin staining of CRUK0935 T1-R5 TRACERx lung cancer PDX model at early P0 passage.
PDX Models

New non-small cell lung cancer (NSCLC) patient-derived-xenograft (PDX) models now available at CancerTools.org

Read More

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.